Health Canada Greenlights Subcutaneous Keytruda SC™ (Pembrolizumab) for Various Cancer Treatments

Written by Emily J. Thompson, Senior Investment Analyst

Source: moomoo

Updated: 3 hours ago

0mins

MRK+0.35%

Should l Buy MRK?

Source: moomoo

Health Canada Approval: Health Canada has approved Keytruda (pembrolizumab) as a subcutaneous formulation for multiple cancer indications.
Treatment Options: This approval expands treatment options for patients with various types of cancer, enhancing accessibility and convenience in administration.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on MRK

Wall Street analysts forecast MRK stock price to fall

16 Analyst Rating

11 Buy

5 Hold

0 Sell

Moderate Buy

Current: 121.410

Low

95.00

Averages

119.53

High

139.00

Current: 121.410

Low

95.00

Averages

119.53

High

139.00

Deutsche Bank

James Shin

Hold

Buy

upgrade

$115 -> $150

2026-02-13

New

Reason

Deutsche Bank

James Shin

Price Target

$115 -> $150

AI Analysis

2026-02-13

New

upgrade

Hold

Buy

Reason

Deutsche Bank analyst James Shin upgraded Merck to Buy from Hold with a price target of $150, up from $115. The firm believes the market is undervaluing Merck due due to Keytruda's looming patent cliff. Deutsche's analysis indicates a "clear path" for the company to navigate the transition effectively, the anlayst tells investors in a research note. The firm believes Merck ,excluding Keytruda, has line of sight to growth, with a trough earnings "formation at hand."

BofA

Jason Gerberry

Buy

maintain

$124 -> $132

2026-02-04

Reason

BofA

Jason Gerberry

Price Target

$124 -> $132

2026-02-04

maintain

Buy

Reason

BofA analyst Jason Gerberry raised the firm's price target on Merck to $132 from $124 and keeps a Buy rating on the shares. Post Q4, the firm reduced its 2026 sales and EPS estimates to reflect greater conservatism around some loss of exclusivity products, U.S. Gardasil sales and Lagevrio, but increased outyear forecasts 2%-3% as it now includes MK-1406 for influenza in its forecast, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MRK

Unlock Now

About MRK

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.